Results 31 to 40 of about 22,911 (183)

A Post-Neurosurgical Infection due to KPC-Producing Klebsiella pneumoniae Treated with Meropenem-Vaborbactam: A Case Report

open access: yesInternational Journal of Infectious Diseases, 2022
This case report describes a patient with post-neurosurgical infection and bacteremia caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae.
Seohyun Choi   +4 more
doaj   +1 more source

In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria

open access: yesAntibiotics, 2023
Background: Despite the availability of new options (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol), it is still very difficult to treat infections caused by metallo-β-lactamase (MBLs)-producers resistant to aztreonam.
Cécile Emeraud   +2 more
doaj   +1 more source

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex

open access: yesMicrobiology Spectrum, 2023
As meropenem-clavulanic acid is recommended for the treatment of drug-resistant tuberculosis, the repurposing of new carbapenem combinations may provide new treatment options, including oral alternatives.
Elin Economou Lundeberg   +11 more
doaj   +1 more source

Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection. [PDF]

open access: yesJ Pediatr Pharmacol Ther
Meropenem/vaborbactam is a combination antibiotic with a carbapenem and a carbapenemase inhibitor typically reserved for extensively drug-resistant bacterial infections, such as carbapenem-resistant Enterobacterales (CRE). Meropenem/vaborbactam is approved by the United States Food and Drug Administration for use in adults for complicated urinary tract
Sano U, Meyers R, Hasan U, Smoke S.
europepmc   +3 more sources

Meropenem/vaborbactam activity in vitro: a new option for Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae treatment

open access: yes, 2021
Aim: Infections by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae represent a major challenge because of limited treatment strategies. New β-lactam/β-lactamase inhibitor associations may help to deal with this challenge.
Romanelli, Federica   +15 more
core   +1 more source

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

open access: yesInternational Journal of Infectious Diseases, 2021
Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI).
Helio S. Sader   +3 more
doaj   +1 more source

New evidence in severe pneumonia: meropenem-vaborbactam

open access: yesRevista Española de Quimioterapia, 2022
The appearance and spread of new mechanisms of bacterial resistance to antibiotics is a serious health problem. One of the most difficult resistance mechanisms to treat is the production of carbapenemases. Carbapenemase KPC is one of those mechanisms with few therapeutic options.
Forteza Guillot, Maria   +2 more
openaire   +3 more sources

Evaluation with E-test of the meropenem/vaborbactam association in carbapenem-resistant and sensitive negative control strains isolates of samples processed at the Laboratory of the Rivoli Hospital

open access: yesMicrobiologia Medica, 2022
Background and aims: Meropenem (Mer) and vaborbactam (Vab) is a combination of a carbapenem and a new β-lactamase inhibitor used in adults to treat different types of infections caused by Gram-negative bacteria.
Giuseppina Amarù   +6 more
doaj   +1 more source

Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations [PDF]

open access: yesClinical Infectious Diseases, 2018
Ceftazidime/avibactam and meropenem/vaborbactam are changing the management of invasive infections due to carbapenem-resistant Enterobacteriaceae (CRE), leading to higher rates of clinical cure, decreased mortality, and decreased rates of acute kidney injury compared with colistin-based regimens.
Jason M, Pogue   +2 more
openaire   +2 more sources

Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant Enterobacteriaceae

open access: yes, 2022
Introduction: The review aims to review the positioning of meropenem-vaborbactam in clinical practice, taking into consideration the characteristics of other available drugs, namely ceftazidime-avibactam, plazomicin, and colistin.
Giamarellos-Bourboulis, E.J.   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy